Study guide

31.2 Oral Candidiasis

Overseas Registration Examination ORE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: ORE Part 1 — Exam Blueprint, Logistics and Strategy

1.1 Structure and Format of ORE Part 1 1.2 The Official Blueprint and Preparing for Practice 1.3 Eligibility, Fees, Attempts and Time Limits

2 Chapter 2: Anatomy of the Head and Neck

2.1 The Trigeminal Nerve and Dental Innervation 2.2 The Facial Nerve and Parotid Region 2.3 The Temporomandibular Joint and Muscles of Mastication 2.4 The Infratemporal Fossa and Spread of Odontogenic Infection

3 Chapter 3: Dental Anatomy, Morphology and Occlusion

3.1 Permanent and Primary Tooth Morphology 3.2 Functional Occlusion: Centric Relation, Guidance and Interferences 3.3 Classifying Occlusion: Angle and BSI Incisor Relationships

4 Chapter 4: Genetics, Embryology and Odontogenesis

4.1 Stages of Odontogenesis and Molecular Signalling 4.2 Amelogenesis and Enamel Microstructure 4.3 Dentinogenesis and the Pulp-Dentine Complex 4.4 Cementum, the Periodontal Ligament and Oral Mucosa 4.5 Genetic and Developmental Dental Anomalies

5 Chapter 5: Oral Biology and Salivary Physiology

5.1 Salivary Gland Anatomy, Microarchitecture and Innervation 5.2 Salivary Secretion, Flow Rates and Autonomic Control 5.3 Salivary Buffering Systems and Protective Macromolecules 5.4 Physiology of Mastication and Deglutition 5.5 Taste, Lingual Papillae and Gustatory Pathways 5.6 Xerostomia, Sjogren's Syndrome and Salivary Diagnostics

6 Chapter 6: Physiology of the Major Body Systems

6.1 Cardiovascular and Respiratory Physiology 6.2 Renal, Endocrine and Gastrointestinal Physiology 6.3 Haematology and Haemostasis 6.4 Neurophysiology, Pain and the Autonomic Nervous System

7 Chapter 7: Bone Biology, Calcium Homeostasis and Healing

7.1 Microstructure and Architecture of Alveolar Bone 7.2 Bone Remodelling and the RANK/RANKL/OPG Axis 7.3 Endocrine Control of Calcium and Phosphate 7.4 Extraction Socket Healing and Ridge Resorption 7.5 Impaired Healing: MRONJ, Osteoradionecrosis and Systemic Risk

8 Chapter 8: Oral Microbiology and Biofilm Ecology

8.1 The Oral Microbiome and Biofilm Development 8.2 Cariogenic Microbiology: Mutans Streptococci and Lactobacilli 8.3 Ecological Hypotheses of Dental Caries 8.4 Biofilm Tolerance and the Case for Mechanical Plaque Control

9 Chapter 9: Immunology Relevant to Oral Disease

9.1 Innate Mucosal Immunity and Gingival Crevicular Fluid 9.2 Cellular Immunity in the Periodontium 9.3 Microbial Pathogenesis: Complexes and Keystone Pathogens 9.4 Host-Mediated Tissue Destruction 9.5 Hypersensitivity Reactions in Dental Practice 9.6 Autoimmune Mucocutaneous Bullous Disease 9.7 Immunodeficiency and Oral HIV Manifestations

10 Chapter 10: General Pathology and Neoplasia

10.1 Cellular Adaptation and Mechanisms of Cell Death 10.2 Inflammation, Wound Healing and Repair 10.3 Principles of Neoplasia and Carcinogenesis 10.4 TNM Staging of Oral Cavity Carcinoma

11 Chapter 11: Statistics and Research Methods

11.1 Study Designs and the Hierarchy of Evidence 11.2 Descriptive and Inferential Statistics 11.3 Diagnostic Test Performance 11.4 Critical Appraisal, Bias and Research Governance

12 Chapter 12: Human Disease: Cardiovascular and Respiratory

12.1 Infective Endocarditis and NICE CG64 12.2 Hypertension and Blood Pressure Thresholds for Dental Care 12.3 Angina, Myocardial Infarction and Antiplatelet Therapy 12.4 Asthma, COPD and Respiratory Emergencies

13 Chapter 13: Human Disease: Endocrine, Haematological and Renal

13.1 Diabetes Mellitus and the Periodontal Axis 13.2 Congenital Bleeding and Clotting Disorders 13.3 Anticoagulants and Antiplatelets: The SDCEP Protocol 13.4 Chronic Kidney Disease and Haemodialysis

14 Chapter 14: Human Disease: Gastrointestinal, Hepatic and Neurological

14.1 Gastrointestinal Disease and Intrinsic Dental Erosion 14.2 Liver Disease, Coagulopathy and Viral Hepatitis 14.3 Epilepsy, Stroke and Transient Ischaemic Attack 14.4 Trigeminal Neuralgia, Bell's Palsy and Giant Cell Arteritis

15 Chapter 15: Oral Aspects of Human Disease

15.1 Oral Manifestations of Systemic Disease 15.2 Orofacial Pain and Temporomandibular Disorders 15.3 Dry Mouth, Altered Taste and Halitosis

16 Chapter 16: Infection Prevention and Control

16.1 The Decontamination Cycle, Sterilization and Waterlines 16.2 Routes of Transmission and Blood-Borne Viruses

17 Chapter 17: Dental Materials

17.1 Dental Amalgam: Metallurgy and UK Regulation 17.2 Resin Composites: Chemistry and Placement 17.3 Dental Adhesive Systems 17.4 Acid Etching, the Hybrid Layer and MMP Degradation 17.5 Glass Ionomer Cements, RMGICs and Compomers 17.6 Impression Materials and Digital Scanning 17.7 Luting Cements and Adhesive Conditioning Protocols 17.8 Dental Ceramics and Cast Alloys 17.9 Gypsum Products, Waxes and Denture Base Polymers

18 Chapter 18: Behavioural Sciences Relevant to Oral Health Care

18.1 Health Behaviour Models and Behaviour Change 18.2 Dental Anxiety and Phobia 18.3 Psychosocial and Sociological Determinants of Oral Health

19 Chapter 19: Patient Assessment and Diagnosis

19.1 History Taking and Clinical Examination 19.2 Special Investigations and Reaching a Diagnosis

20 Chapter 20: Treatment Planning and Risk-Based Care

20.1 Treatment Planning and Sequencing 20.2 Risk Assessment, Recall Intervals and Preventive Planning

21 Chapter 21: Cariology and Caries Risk Assessment

21.1 Caries Pathogenesis and the Stephan Curve 21.2 Histopathology of Enamel and Dentinal Caries 21.3 Caries Diagnosis, ICDAS and Risk Assessment

22 Chapter 22: Operative Dentistry and Minimal Intervention

22.1 Minimal Intervention and Selective Caries Removal 22.2 Pulp Vitality Assessment and Biological Pulp Capping 22.3 Cavity Design, the C-Factor and Margin Geometry

23 Chapter 23: Endodontics

23.1 Pulp Histology and the Low-Compliance Environment 23.2 Pulpal Neurophysiology and Dentine Hypersensitivity 23.3 Pulpal and Periapical Diagnostic Terminology 23.4 Endodontic Diagnostic Testing 23.5 Access Cavity Design and Canal Configurations 23.6 Working Length Determination and Canal Preparation 23.7 Chemical Disinfection and Irrigant Activation 23.8 Medicaments, Obturation Materials and Techniques 23.9 Restoring Endodontically Treated Teeth 23.10 Endodontic Emergencies, Cracked Teeth and Root Fracture

24 Chapter 24: Periodontology

24.1 The 2018 Classification and Periodontal Health 24.2 Plaque-Induced and Non-Plaque-Induced Gingival Disease 24.3 Staging and Grading Periodontitis 24.4 Peri-Implant Disease and Systemic Risk Factors 24.5 The Basic Periodontal Examination 24.6 Simplified BPE in Children and Full Periodontal Charting 24.7 Furcation Involvement, Mobility and Occlusal Trauma 24.8 The BSP Stepwise Treatment Framework 24.9 Periodontal Instrumentation and Healing 24.10 Re-Evaluation, Endpoints and Periodontal Surgery 24.11 Crown Lengthening, Supracrestal Attachment and Supportive Care

25 Chapter 25: Fixed Prosthodontics

25.1 Biomechanical Principles of Tooth Preparation 25.2 Margin Design and the Supracrestal Attachment 25.3 Bridge Design and Resin-Bonded Bridges 25.4 Gingival Retraction, Provisionals and Temporary Cements

26 Chapter 26: Removable Prosthodontics

26.1 Removable Partial Dentures: Classification, Design and Surveying 26.2 Complete Dentures: Principles, Impressions and Jaw Registration

27 Chapter 27: Paediatric Dentistry

27.1 Primary Tooth Anatomy and Caries Management Strategies 27.2 Preformed Metal Crowns and the Hall Technique 27.3 Pulp Therapy in Primary Teeth 27.4 Extractions in the Primary Dentition 27.5 Non-Pharmacological Behaviour Management 27.6 Inhalation Sedation in Paediatric Dentistry 27.7 The Developing Dentition and Space Management 27.8 Serial Extraction and Non-Nutritive Sucking Habits

28 Chapter 28: Dental Traumatology

28.1 Trauma Assessment and Fractures of Permanent Teeth 28.2 Luxation Injuries, Avulsion and Replantation 28.3 Primary Tooth Trauma and Splinting Specifications

29 Chapter 29: Orthodontics

29.1 Extraoral Orthodontic Assessment 29.2 Intraoral Occlusal Assessment 29.3 Skeletal Pattern and Cephalometric Analysis 29.4 IOTN and NHS Treatment Eligibility 29.5 Upper Removable Appliances 29.6 Functional and Fixed Appliances 29.7 Biology of Orthodontic Tooth Movement 29.8 Orthodontic Risks and Retention

30 Chapter 30: Oral Surgery

30.1 Exodontia Biomechanics and Instrument Selection 30.2 Surgical Flap Design, Bone Removal and Suturing 30.3 Third Molar Surgery and NICE Guidance 30.4 Dry Socket and Oroantral Communication 30.5 Odontogenic Infection and Fascial Space Spread

31 Chapter 31: Oral Medicine

31.1 Recurrent Aphthous Stomatitis 31.2 Oral Candidiasis 31.3 Viral Oral Infections 31.4 Reactive Soft Tissue Lesions and the Epulides 31.5 Oral Potentially Malignant Disorders 31.6 Oral Squamous Cell Carcinoma, Urgent Referral and Biopsy

32 Chapter 32: Oral Pathology

32.1 Odontogenic and Non-Odontogenic Cysts 32.2 Odontogenic Tumours 32.3 Obstructive and Reactive Salivary Gland Disease 32.4 Salivary Gland Neoplasms

33 Chapter 33: Therapeutics and Prescribing

33.1 Local Anaesthetic Chemistry and Mechanism of Action 33.2 UK Local Anaesthetic Formulations 33.3 Vasoconstrictors, Maximum Doses and Systemic Toxicity 33.4 Analgesics for Acute Dental Pain 33.5 Antimicrobial Stewardship and First-Line Regimens 33.6 Antifungal and Antiviral Therapeutics

34 Chapter 34: Medical Emergencies in Dental Practice

34.1 The ABCDE Approach and the Emergency Drug Kit 34.2 Anaphylaxis and Acute Coronary Syndrome 34.3 Hypoglycaemia, Acute Asthma and Seizures 34.4 Syncope, Adrenal Crisis, Choking and Resuscitation

35 Chapter 35: Dental Radiology and Radiation Protection

35.1 Radiation Physics, Filtration and Collimation 35.2 Intraoral, Bitewing and Occlusal Projections 35.3 Dental Panoramic Tomography: Principles, Positioning and Errors 35.4 Lateral Cephalometry and Cone Beam CT 35.5 Systematic Reporting and Radiographic Caries Diagnosis 35.6 Radiology of Periodontal Bone Loss and Jaw Lesions 35.7 Radiographic Quality Assurance 35.8 IRR17 and IR(ME)R 2017

36 Chapter 36: Special Care Dentistry and Conscious Sedation

36.1 Special Care Dentistry, Risk Stratification and Sedation Principles 36.2 Inhalation Sedation with Nitrous Oxide 36.3 Intravenous Sedation with Midazolam 36.4 Oral Sedation and General Anaesthesia Referral

37 Chapter 37: Dental Public Health

37.1 Delivering Better Oral Health and the Fluoride Toolkit 37.2 Oral Health Epidemiology and Indices 37.3 Inequalities, Water Fluoridation and Population Prevention 37.4 NHS Dental Services, Access and Commissioning

38 Chapter 38: Communication and Interpersonal Skills

38.1 Patient Communication and Shared Decision-Making 38.2 Breaking Bad News, Complaints and the Duty of Candour 38.3 Referrals, Records and Communication with the Team

39 Chapter 39: Consent and Capacity

39.1 Valid Consent and the Montgomery Standard 39.2 The Mental Capacity Act 2005 39.3 Best Interests Decisions and Lasting Power of Attorney 39.4 Consent in Children and Young People 39.5 Safeguarding Children and Vulnerable Adults 39.6 Confidentiality, Data Protection and Lawful Disclosure

40 Chapter 40: Clinical Professionalism and the GDC

40.1 The General Dental Council and Standards Principles 1 to 4 40.2 GDC Standards: Principles 5 to 9 40.3 The GDC Fitness to Practise Process 40.4 Clinical Governance and the Audit Cycle

41 Chapter 41: Health and Safety Law in Dental Practice

41.1 Health and Safety Legislation, COSHH, RIDDOR and Sharps

42 Chapter 42: Self-Management and Professional Development

42.1 Enhanced CPD, Lifelong Learning and Reflective Practice 42.2 Managing Time, Stress and Clinical Wellbeing 42.3 Leadership, Delegation and Practice Management

31.2 Oral Candidiasis

Key Takeaways Explain This Topic AI

Pseudomembranous candidiasis wipes off leaving an erythematous base; chronic hyperplastic candidiasis does not and carries malignant potential.

Denture stomatitis is Newton type I, II or III and requires the denture to be left out at night for at least 6 to 8 hours and disinfected.

Nystatin suspension is given as 100,000 units per mL, 1 mL four times daily after meals for 7 to 14 days.

Miconazole gel and fluconazole both potentiate warfarin through CYP inhibition and can push the INR above 10.

Chronic hyperplastic candidiasis at the retrocommissural buccal mucosa is an oral potentially malignant disorder requiring biopsy.

Last updated: September 2026

Oral Candidiasis

Oral candidiasis is an opportunistic fungal infection primarily caused by the dimorphic yeast Candida albicans , an endogenous commensal organism present in the oral microbiota of 40–60% of healthy individuals. Transformation from benign budding blastospore (yeast) to invasive, tissue-penetrating pseudo-hyphae and true hyphae occurs when host local or systemic immune surveillance is disrupted.

Predisposing Local and Systemic Factors

Candida is an opportunistic pathogen; successful management mandates identifying and eliminating underlying predisposing factors:

Local Factors:

Removable prostheses: Continuous night-time denture wear, poor acrylic hygiene, fitting-surface microporosity, low pH and anaerobic microenvironment beneath maxillary dentures.

Inhaled Corticosteroids: Fluticasone or beclometasone inhalers used for asthma/COPD without a spacer device or failing to rinse the mouth with water following inhalation.

Salivary gland hypofunction (Xerostomia): Loss of antimicrobial histatins, calprotectin, and secretory IgA due to Sjögren's syndrome, therapeutic head and neck radiotherapy, or polypharmacy (anticholinergics, tricyclic antidepressants, diuretics).

Tobacco smoking: High carbohydrate/hydrocarbon load enhances candidal adhesion.

Topical antimicrobial agents: Broad-spectrum antiseptic mouthwashes disrupting bacterial antagonism.

Systemic Factors:

Systemic broad-spectrum antibiotic therapy: Eradication of normal competing oral flora allows unrestrained candidal overgrowth.

Immunosuppressive states: HIV infection (CD4+ T-cell depletion <200/μL is strongly heralded by pseudomembranous candidiasis), cytotoxic chemotherapy, organ transplantation, primary immunodeficiencies.

Endocrine disorders: Poorly controlled Diabetes Mellitus (hyperglycaemic saliva provides a substrate for candidal growth and impairs neutrophil chemotaxis/phagocytosis), Addison's disease, hypoparathyroidism (autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy / APECED).

Nutritional deficiencies: Severe iron deficiency anaemia, vitamin B12 or folate deficiency.

Extremes of life: Neonates (immature immune system and lack of competing oral microflora) and frail elderly individuals.

  • Clinical Subtypes of Oral Candidiasis Oral Candidiasis
  • │
  • ┌────────────────────────┬────────┴────────┬────────────────────────┐
  • ▼ ▼ ▼ ▼
  • Pseudomembranous Erythematous Hyperplastic Angular Cheilitis
  • Creamy white plaques • Fiery red mucosa • Firm white plaques • Commissural crusting
  • WIPES OFF • Painful burning • NON-WIPEABLE • C. albicans + S. aureus
  • Raw erythematous base • Denture-related • Retromolar / cheek • Reduced vertical
  • Infants, HIV, steroids • Newton types I-III• Dysplasia risk (5-10%) dimension (VDO)

Pseudomembranous Candidiasis ("Thrush"):

Clinical Picture: Superficial, soft, creamy-white or pale-yellow curdy plaques resembling milk curds or cottage cheese, distributed across the buccal mucosa, soft palate, dorsum of the tongue, and labial sulci.

Diagnostic Hallmark: The plaques can be easily scraped or wiped off with a dry gauze swab or tongue depressor , revealing an underlying erythematous, raw, bleeding, or painful base.

Microscopy: Gram stain or PAS (Periodic acid–Schiff) stain reveals desquamated epithelial cells, polymorphonuclear leukocytes, and abundant branching candidal pseudo-hyphae and blastospores.

Setting: Common in infants, elderly denture wearers, patients on high-dose inhaled or systemic steroids, and immunosuppressed individuals (classic opportunistic hallmark of undiagnosed HIV/AIDS).

Erythematous (Atrophic) Candidiasis:

Characterized by bright red, depapillated, inflamed mucosal surfaces without white pseudomembranes. Two primary presentations exist:

Acute Erythematous Candidiasis (Acute Antibiotic Stomatitis): Follows a course of broad-spectrum antibiotics (e.g., amoxicillin, cephalosporins). Presents as generalised, painful, fiery red mucosal erythema with marked depapillation and loss of filiform papillae on the dorsum of the tongue, creating a smooth, glazed, burning ("raw beef") tongue.

Chronic Erythematous Candidiasis (Denture-Related Stomatitis): The most common form of oral candidiasis in general dental practice. Confined strictly to the mucosal area covered by the fitting surface of an upper complete or partial acrylic denture. Characteristically asymptomatic or producing mild burning.

Newton's Classification of Denture Stomatitis Newton Class: T y p e I ( P i n p o i n t ) ⟶ T y p e I I ( D i f f u s e E r y t h e m a ) ⟶ T y p e I I I ( P a p i l l a r y H y p e r p l a s i a ) \text{Newton Class: } \mathbf{Type\ I\ (Pinpoint)} \longrightarrow \mathbf{Type\ II\ (Diffuse\ Erythema)} \longrightarrow \mathbf{Type\ III\ (Papillary\ Hyperplasia)} Newton Class: Type I ( Pinpoint ) ⟶ Type II ( Diffuse Erythema ) ⟶ Type III ( Papillary Hyperplasia )

Newton Type Clinical Appearance Histological / Clinical Correlate

Type I Localised pinpoint hyperaemic patches Mild, focal inflammation centered around palatal minor salivary duct orifices.

Type II Diffuse, generalised erythema covering the entire denture-bearing palatal mucosa Uniformly bright red, smooth, congested mucosa sharply demarcated by the outline of the denture base.

Type III Inflammatory papillary hyperplasia (granular cobblestone mucosa) Nodular, verrucous, or papillary mucosal proliferation, most prominent in the central hard palate vault. Frequently exacerbated by heavy suction and poor denture hygiene.

Chronic Hyperplastic Candidiasis (Candidal Leukoplakia):

Clinical Picture: Dense, firm, rough, translucent to opaque white plaques located predominantly on the retrocommissural buccal mucosa (bilaterally) and occasionally the lateral margins of the tongue.

Diagnostic Hallmark: Unlike pseudomembranous thrush, hyperplastic candidiasis CANNOT be wiped or scraped off .

Malignant Transformation Potential: This is an established Oral Potentially Malignant Disorder (OPMD) . It carries an estimated 5% to 10% risk of malignant transformation to oral squamous cell carcinoma. Histopathology reveals candidal hyphae invading perpendicular to the superficial parakeratinised layer, parakeratosis, microabscesses of polymorphonuclear leukocytes in the upper spinous layer ( Munro microabscesses ), and variable degrees of epithelial dysplasia.

Management: Requires definitive incisional biopsy to evaluate dysplasia, followed by prolonged systemic antifungal therapy (e.g., fluconazole for 2–4 weeks) and surgical excision if dysplasia persists.

Angular Cheilitis (Perlèche):

Clinical Picture: Symmetrical or unilateral erythematous fissuring, maceration, crusting, and ulceration at the labial commissures (angles of the mouth).

Microbiology: A mixed polymicrobial infection involving Candida albicans (~60%) , Staphylococcus aureus (~35%) , and occasionally beta-haemolytic streptococci.

Aetiological Drivers:

Reduced Vertical Dimension of Occlusion (VDO): Overclosure due to severe tooth wear or worn, ill-fitting dentures creates deep, folded cutaneous creases at the corners of the mouth, continuously macerated by pooled saliva.

Incompetent lip seal and drooling in elderly patients.

Underlying reservoir: Almost always co-exists with an intraoral candidal reservoir (e.g., untreated Newton Type II denture stomatitis).

Haematinic deficiency: Iron deficiency anaemia, riboflavin (B2), and B12 deficiencies.

Antifungal Pharmacology & Critical Clinical Interactions

Successful management requires treating both the oral mucosa and the prosthetic appliance:

Denture Hygiene Protocol:

The denture must be removed at night (at least 6–8 hours daily).

Mechanical cleansing with a soft brush and neutral soap.

Chemical disinfection: Soak all-acrylic dentures in 0.1% sodium hypochlorite (Milton solution) for 15–30 minutes daily (kills fungal spores). Contraindication: Sodium hypochlorite must NEVER be used on dentures with metal components (cobalt-chromium clasps/frameworks) because it causes severe oxidation, pitting, and corrosion. For metal-containing dentures, soak in 0.2% chlorhexidine gluconate or alkaline peroxide solutions.

Topical Antifungal Agents:

Nystatin Oral Suspension (100,000 units/mL): Polyene antifungal that binds to fungal cell membrane ergosterol, creating pores that leak potassium and cellular contents. Dosage: 1 mL rinse and hold in the mouth for several minutes before swallowing, 4 times daily (qds) after meals for 7–14 days. Safe in pregnancy and lactation as it has negligible systemic absorption.

Miconazole Oromucosal Gel (20 mg/g): Imidazole antifungal inhibiting 14-α-demethylase, impairing ergosterol synthesis. Dosage: 2.5 mL applied to the oral mucosa (and fitting surface of the clean denture) 4 times daily after food for 7–14 days (continue for 48 hours after lesions resolve).

Caution

Life-Threatening Clinical Trap — Miconazole and Warfarin Interaction: Miconazole is a potent, irreversible inhibitor of the hepatic cytochrome P450 enzyme CYP2C9 . CYP2C9 is the primary enzyme responsible for metabolising the active S-enantiomer of warfarin . Even topical or oromucosal administration of miconazole gel undergoes sufficient systemic absorption to severely inhibit warfarin breakdown. This causes a precipitous, catastrophic spike in the patient's International Normalized Ratio (INR) , frequently driving the INR >10.0 and precipitating fatal intracerebral, gastrointestinal, or retroperitoneal haemorrhage. Miconazole (oral gel or cream) is ABSOLUTELY CONTRAINDICATED in any patient taking warfarin. In patients taking warfarin, use Nystatin as the first-line agent, as nystatin is not absorbed and exhibits zero CYP interactions.

Systemic Antifungal Agents:

Fluconazole Capsules (50 mg / 100 mg): Triazole antifungal. Reserved for immunocompromised patients, widespread refractory candidiasis, chronic hyperplastic candidiasis, or chronic mucocutaneous candidiasis. Standard dosage: 50 mg daily orally for 7 to 14 days (100 mg daily for 2–3 weeks in hyperplastic candidiasis). Monitor liver function tests in prolonged therapy; note that fluconazole also inhibits CYP enzymes and interacts with warfarin, phenytoin, and sulfonylureas.